EpilepsyICARENCT07599150
Intracranial CArtography of Cortical Contribution to Respiratory Load Compensation in Epilepsy
A study testing SEEG monitoring, Comprehensive respiratory monitoring and Cardio-respiratory monitoring in people with Epilepsy and SUDEP, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
30% of patients with epilepsy suffer from drug-resistant seizures and have a greater risk of premature mortality than the general population. Among all causes of death, the most frequent is SUDEP, for sudden and unexpected death in epilepsy patients. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- What is being tested?
- SEEG monitoring, Comprehensive respiratory monitoring and Cardio-respiratory monitoring
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 17 Sep 2026to 17 Sep 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
- Aged 18 to 55 years old
- Diagnosis of drug-resistant focal epilepsy, as defined by the International League Against Epilepsy 20
- Patients undergoing SEEG as part of presurgical evaluation
- At least one SEEG electrode localized in the perisylvian cortex
- At least one SEEG electrode localized in the premotor cortex
Who cannot join
- 1. Ongoing or chronic respiratory and/or cardiac insufficiency and/or ischemic cardiac disease 2. History of stroke in the last 5 years 3. Intracranial hypertension related to space-occupying lesion in the brain 4. Pregnant, parturient, or breastfeeding women 5. Individuals receiving psychiatric care 6. Individuals deprived of their liberty by judicial or administrative decision 7. Adults subject to legal protection measures (guardianship, curatorship) 8. Individuals not affiliated with a social security scheme or beneficiaries of a similar scheme
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Neurologie Fonctionne et d'Epileptologie Hôpital Neurologique Pierre WERTHEIMER
Bron, Rhone, 69500
sylvain RHEIMS, Pr, 04 72 35 70 44 ext. +33, sylvain.rheims@chu-lyon.fr
About this study
30% of patients with epilepsy suffer from drug-resistant seizures and have a greater risk of premature mortality than the general population. Among all causes of death, the most frequent is SUDEP, for sudden and unexpected death in epilepsy patients. SUDEP typically occurs after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase. Most of patients with drug-resistant seizures demonstrate transient peri-ictal apnea and hypoxemia especially in the aftermath of a GCS. Experimental and clinical data suggest that most SUDEP primarily result from a fatal seizure-related respiratory arrest 5. Apnea was the primary cause of death in several epilepsy models. In patients whose SUDEP had occurred during long-term video-EEG monitoring, we observed fatal postictal central apnea after a nocturnal GCS in all SUDEP. Accordingly, it is currently hypothesized that in a subgroup of patients, repetition of seizures may contribute to chronic alteration of respiratory regulation which may increase the risk of fatal postictal central respiratory arrest.
Central regulation of autonomic function is ensured by the so-called Central Autonomic Network (CAN), which anatomy in humans has primarily been investigated in neuroimaging studies or using intraEEG (iEEG) data in patients with drug-resistant focal epilepsy undergoing presurgical evaluation with intracerebral electrodes. Central regulation of breathing primarily rely on brainstem, especially the preBötzinger complex for rhythm generation and the retrotrapezoid nucleus and dorsal raphe for chemoreception, especially ventilatory response to hypercapnia. However, through an intricated structures connecting these regions, this respiratory signal projects to a network of cortical and subcortical regions mainly including the limbic and sensorimotor cortical areas. Studies in patients undergoing iEEG reinforced the role of limbic and paralimbic structures, with transient central apnea elicited by direct electrical stimulation of amygdala, hippocampus, anterior parahippocampal, and antero-mesial fusiform gyri. However, our group also reported transient hypoxemia could be elicited by cortical direct electrical stimulation outside the temporo-limbic structures, most commonly after stimulation of the perisylvian cortex. Importantly, our group recently showed that involvement of this perisylvian cortex in the epileptogenic zone is a strong risk factor of SUDEP, reinforcing the importance of further studying its integration in the cortical control of respiration.
The involvement of cortical control of ventilation is particularly important to ensure expiratory load compensation, a typical situation after GCS, which is associated with airway obstruction, especially when the face is positioned into the pillow. This cortical component of the physiological response to experimental expiratory loads was investigated in healthy subjects through the study of EEG activity during an expiratory load compensation protocol. Accordingly, EEGs were processed by ensemble averaging expiratory time-locked segments and examined for pre-expiratory EEG potentials, defined as a slow negative shift from the baseline signal preceding expiration, and suggestive of cortical preparation of expiration. Expiratory load compensation was associated with EEG premotor potential presumably involving the supplementary motor area. However, because of the limited spatial resolution of scalp EEG, the organization of cortical neural sources involved in this expiratory load compensation or during response to hypercapnia, especially the interaction between the premotor cortex, the sensorimotor cortical areas and the perisylvian cortex is unknown.
- Being tested
- SEEG monitoring, Comprehensive respiratory monitoring, Cardio-respiratory monitoring, Expiratory load compensation, Hypercapnic challenge
- Keywords
- Epilepsy, SUDEP, respiratory challenges, evoked potentials
- Medical subject headings
- Epilepsy, Sudden Unexpected Death in Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SEEG monitoringProcedure or surgery
Patients will be recruited among adult patients suffering from drug-resistant focal epilepsy who undergo SEEG monitoring at the Epilepsy Department of the Neurological Hospital. The study will be offered to patients during the hospitalization.
Comprehensive respiratory monitoringProcedure or surgery
In addition to SEEG monitoring, all participants will undergo comprehensive respiratory monitoring in order to collect respiratory data (tidal volume, VE, and respiratory rate) and gas exchange (PETO2 and PETCO2).
Cardio-respiratory monitoringProcedure or surgery
In addition to SEEG channels, cardio-respiratory monitoring consisting of pulse oximetry, respiratory efforts (thoracic and abdominal) and EKG recordings will be performed.
Expiratory load compensationProcedure or surgery
Expiratory load compensation will be assessed in the patient's room in the epilepsy monitoring unit. Patients will breathe through a facemask connected in series to a bidirectional pneumotach and a three-way T-shaped valve. The second port on the three-way valve will be open to room air, and third port will be connected to a CE-marked PEEP valve (PEEP 20 valve, Ambu A/S Denmark) allowing to adjust airflow resistance during expiration from 0.15-2.0 kPa (1.5-20 cmH2O). Respired air will be continuously sampled at the mouth and analyzed for fractional concentrations of O2 and CO2.
Hypercapnic challengeProcedure or surgery
The patient breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the patient breathes ambient air and his or her breathing is measured. Then, after a few minutes, the patient is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
QuestionnairesOther
Caffeine intake Self-report the degree of "breathlessness" during Expiratory load compensation using a visual analogue scale Self-report the degree of "breathlessness
| Study group | Role | What they receive |
|---|---|---|
| Patients with drug-resistant epilepsy | Experimental | Patients with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, who undergo SEEG as part of presurgical evaluation of epilepsy.
In addition to SEEG monitoring, the following procedures will be carried out as part of the research:
* Comprehensive respiratory monitoring
* Cardio-respiratory monitoring
* Expiratory load compensation
* Hypercapnic challenge
* Questionnaires completion. Receives: Procedure: SEEG monitoring; Procedure: Comprehensive respiratory monitoring; Procedure: Cardio-respiratory monitoring; Procedure: Expiratory load compensation; Procedure: Hypercapnic challenge; Other: Questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cortical localization of pre-expiratory potentials (via SEEG) during HETL (20 cmH₂O) in drug-resistant epilepsy
Localization of SEEG contacts will use the anatomical MRI images performed in clinical routine. Pre-expiratory potentials are defined as a slow negative shift from the baseline signal starting between 2 and 0.5 s before the onset of expiration. Both visual and statistical analyses will be used to conclude on the presence of significant pre-expiratory potentials over each recording contact, using the same approach as the one our group used in the past in another physiological paradigm.
Measured: Through study completion, an average of 1 year
Secondary outcomes (8)
dentification of cortical SEEG contacts showing pre-expiratory potentials under 10 cmH₂O low expiratory threshold load (LETL) in drug-resistant epilepsy
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Measured: Through study completion, an average of 1 year
Cortical localization of SEEG contacts exhibiting pre-expiratory potentials during a hypercapnic challenge (HyperCO₂) in patients with drug-resistant epilepsy.
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Measured: Through study completion, an average of 1 year
Latency (ms) of the pre-expiratory potentials in each condition (HETL, LETL, HyperCO2)
Measured: Through study completion, an average of 1 year
Value of hypercapnic ventilatory response (HCVR)* in each condition (HETL, LETL, HyperCO2)
HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2 and is a marker of central chemoreception
Measured: Through study completion, an average of 1 year
Number of focal to bilateral tonic-clonic seizures during the 18 months preceding the SEEG
SUDEP typically occurs after a nocturnal seizure , and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS) , suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase.
Measured: Inclusion visit
Localization of the SEEG contacts included in the epileptogenic zone (EZ)
The EZ corresponds to cortical regions that directly contribute by their abnormal synchronization to seizure initiation and which surgical removal would be required to result in seizure freedom. Its identification, which is the main medical of SEEG monitoring for presurgical evaluation, combines the analysis of all data collected during the SEEG (inter-ictal, seizures and direct electrical stimulations).
Measured: Inclusion visit
Current and past mean daily intake of caffeine (mg/day)
Current usual caffeine intake and the one over the last ten years will be assessed by a validated self-survey filled-in at home by the patient and, if needed, the help of the caregiver filled between the inclusion visit and the hospitalization.
Measured: Inclusion visit
Respiratory discomfort of the experiment during each condition (HETL, LETL, HyperCO2)
The degree of "respiratory discomfort" will be self-assessed by the subjects on a visual analog scale (VAS) . The subjects were asked to set the cursor on a 10-cm horizontal line, between the descriptions "no respiratory discomfort" on the left and "intolerable respiratory discomfort on the right.
Measured: Immediately after the respiratory challenges.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2026
- Study start17 Sep 2026
- Primary completion17 Sep 2028 (estimated)
- Study completion17 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Patients with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, who undergo SEEG as part of presurgical evaluation of epilepsy.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07599150
- Sponsor's protocol ID
- 69HCL26_0383
- Acronym
- ICARE
- Status last verified
- May 2026
- First submitted
- 6 May 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No